Back to article: Cristae architecture is determined by an interplay of the MICOS complex and the F1FO ATP synthase via Mic27 and Mic10


FIGURE 5: Mic10 is physically linked to the F1FO-ATP synthase. (A) Isolated wildtype- (WT), Δmic27-, Δmic10– and Δsu e-mitochondria were treated with the chemical crosslinker MBS (m-maleimidobenzoyl-N-hydroxysuccinimideester). Wild type mitochondria treated with DMSO served as a negative control. Crosslinked proteins were analyzed by SDS-PAGE and Western blotting. A crosslink of Mic27 and Mic10 (Mic27/Mic10) was identified at 35 kDa and a crosslink of Mic10 and Su e (Mic10/Su e) at 20 kDa. (B) Chemical crosslinking was performed with isolated mitochondria of indicated yeast strains: wild type (WT), Δmic27, Δmic60, Δmic10, Δmic26, Δmic12 and Δmic19. (C) Immunoprecipitation of Mic27-Mic10 crosslink. Isolated wild type- (WT) or Δmic27-mitochondria were treated or not with the crosslinker MBS, solubilized with digitonin (4g/g) and co-immunoprecipitation using a purified anti-Mic27 (right part) antibody was performed. As negative controls, mitochondria not treated with MBS and the corresponding deletion strain were used. The asterisk (*) indicates a nonspecific band of the anti-Mic60 antibody. (D) Schematic representation of the described chemical crosslinks of Mic10 with Mic27 and Su e. (E) Isolated wild type- (WT), Δmic10– and Δmic27-mitochondria were solubilized with digitonin (4g/g) and co-immunoprecipitation using a purified anti-Mic10 (middle part) or anti-Mic27 (right part) antibody was performed. As negative controls, mitochondria treated with the corresponding pre-immune serum (PI) and the corresponding deletion strains were used. The asterisk (*) indicates a nonspecific band of the anti-Mic60 antibody.

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this. Please refer to our "privacy statement" and our "terms of use" for further information.

Close